EcoDrugPlus

Dopamine Receptor D4

Ensembl ID : ENSPNAG00000007464
Gene Symbol: DRD4
3 Cross references
235 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSPNAG00000017601
Gene Symbol: LOC108430106
3 Cross references
212 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2-Like

Ensembl ID : ENSPNAG00000027497
Gene Symbol: LOC108427153
3 Cross references
200 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSPNAG00000002597
Gene Symbol: ENPP2
3 Cross references
226 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSPNAG00000003188
Gene Symbol: EGLN1
3 Cross references
206 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSPNAG00000009484
Gene Symbol: EGLN2
3 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSPNAG00000008631
Gene Symbol: EGLN3
3 Cross references
202 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSPNAG00000013479
Gene Symbol: EPAS1
3 Cross references
212 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSPNAG00000009861
Gene Symbol: EPAS1
3 Cross references
150 Possible Orthologues:

Endothelin B Receptor

Ensembl ID : ENSPNAG00000016141
Gene Symbol: LOC108434743
3 Cross references
196 Possible Orthologues:

Endothelin B Receptor-Like

Ensembl ID : ENSPNAG00000024693
Gene Symbol: LOC108435575
3 Cross references
197 Possible Orthologues:

Endothelin B Receptor-Like

Ensembl ID : ENSPNAG00000018703
Gene Symbol: LOC108429589
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).